Fleet Enema Pead may be available in the countries listed below.
Sodium Phosphate is reported as an ingredient of Fleet Enema Pead in the following countries:
International Drug Name Search
Insuman Comb 30 may be available in the countries listed below.
Insulin Injection, Biphasic Isophane human (a derivative of Insulin Injection, Biphasic Isophane) is reported as an ingredient of Insuman Comb 30 in the following countries:
International Drug Name Search
Relieving symptoms of sinus congestion, pressure, runny nose, and sneezing due to colds, upper respiratory infections, and allergies. It may also be used for other conditions as determined by your doctor.
Dexbrompheniramine/Pseudoephedrine Sustained-Release Tablets are an antihistamine and decongestant combination. The antihistamine works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing. The decongestant promotes sinus and nasal drainage, which relieves congestion and pressure.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Dexbrompheniramine/Pseudoephedrine Sustained-Release Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Dexbrompheniramine/Pseudoephedrine Sustained-Release Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Dexbrompheniramine/Pseudoephedrine Sustained-Release Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Dexbrompheniramine/Pseudoephedrine Sustained-Release Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Dexbrompheniramine/Pseudoephedrine Sustained-Release Tablets.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; drowsiness; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor; trouble sleeping; vision changes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Dexbrompheniramine/Pseudoephedrine side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.
Store Dexbrompheniramine/Pseudoephedrine Sustained-Release Tablets at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Dexbrompheniramine/Pseudoephedrine Sustained-Release Tablets out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Dexbrompheniramine/Pseudoephedrine Sustained-Release Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Generic Name: daclizumab (dah KLIH zyoo mab)
Brand Names: Zenapax
Daclizumab is an immunosuppressant. Immunosuppressants decrease the actions of the body's immune system.
Daclizumab is used to prevent the body from rejecting a transplanted kidney. Daclizumab is usually used as part of a treatment regimen including other medications.
Daclizumab may also be used for purposes other than those listed in this medication guide.
Because it may cause serious side effects, daclizumab should only be prescribed by a doctor experienced in immunosuppressive therapy and the management of organ transplant patients. Discuss the risks and benefits of using this medication with your doctor.
Treatment with an immunosuppressant such as daclizumab may increase the risk of developing certain types of cancer (e.g., lymphoma). Talk to your doctor about the risks and benefits of using this medication.
Because it may cause serious side effects, daclizumab should only be prescribed by a doctor experienced in immunosuppressive therapy and the management of organ transplant patients. Discuss the risks and benefits of using this medication with your doctor.
Before using daclizumab, tell your doctor if you
have used daclizumab in the past;
have had a previous allergic reaction to daclizumab;
have any active or chronic viral, bacterial, or fungal infection; or
have a suppressed immune system or take medications that may suppress the immune system (e.g., medicines to prevent rejection of a transplanted organ, some cancer medicines, others).
You may not be able to use daclizumab, or you may require a dosage adjustment or special monitoring if you have any of the conditions listed above.
Daclizumab is administered as an intravenous (into the vein) injection. In most cases, your healthcare provider will administer daclizumab in a hospital or clinic setting. If you are using daclizumab at home, your healthcare provider will give you detailed instructions regarding preparation, administration, and storage of the medication.
The first dose of daclizumab is usually administered within 24 hours of the kidney transplant. Four additional doses are then given at 14 day intervals following transplantation.
When mixing the solution for injection, the bag should be gently inverted to ensure mixing. Do not shake the mixture.
After mixing the solution for injection, it should be used within 4 hours. If the mixture cannot be used within 4 hours, it should be refrigerated between 36 and 46 degrees Fahrenheit (2 and 8 degrees Celsius) for up to 24 hours. If it is not used within 24 hours, it must be discarded.
Your doctor may want you to have blood tests or other medical evaluations during treatment with daclizumab to monitor progress and side effects.
Your healthcare provider will store daclizumab as directed by the manufacturer. If you are using daclizumab at home, your healthcare provider will give you detailed storage instructions.
Contact your doctor if you miss a dose of daclizumab.
Symptoms of a daclizumab overdose are not known.
Daclizumab can lower the activity of the immune system making you susceptible to infections. Avoid contact with people who have colds, the flu, or other contagious illnesses. Contact your doctor immediately if you develop any signs of illness or infection.
Talk to your doctor before receiving any vaccines during treatment with daclizumab. Some vaccines may not be effective, or may be harmful, if received during treatment with daclizumab. In addition, avoiding close contact with people who have recently been vaccinated with a "live" vaccine (e.g. oral polio vaccine, nasal influenza vaccine) may be recommended. There is a chance that the virus can be passed on to you.
Tell your doctor and dentist that you are using this medication before having surgery and before starting any other medicines.
Treatment with an immunosuppressant such as daclizumab may increase the risk of developing certain types of cancer (e.g., lymphoma). Talk to your doctor about the risks and benefits of using this medication.
Other, less serious side effects may also occur. Continue to use daclizumab and notify your doctor if you experience
upset stomach, nausea, or vomiting;
diarrhea or constipation;
tremor or dizziness;
headache; or
swelling of the hands, feet or legs.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Organ Transplant -- Rejection Prophylaxis:
For the prophylaxis of acute organ rejection in patients receiving renal transplants: 1.0 mg/kg administered via a peripheral or central vein over a 15 minute period. The standard course of therapy includes 5 doses. The first dose should be given no more than 24 hours before transplantation. The four remaining doses should be given at intervals of 14 days.
Usual Pediatric Dose for Organ Transplant -- Rejection Prophylaxis:
>= 1 year:
For the prophylaxis of acute organ rejection in patients receiving renal transplants: 1.0 mg/kg administered via a peripheral or central vein over a 15 minute period. The standard course of therapy includes 5 doses. The first dose should be given no more than 24 hours before transplantation. The four remaining doses should be given at intervals of 14 days.
Talk to your doctor before receiving any vaccines during treatment with daclizumab. Some vaccines may not be effective, or may be harmful, if received during treatment with daclizumab. In addition, avoiding close contact with people who have recently been vaccinated with a "live" vaccine (e.g. oral polio vaccine, nasal influenza vaccine) may be recommended. There is a chance that the virus can be passed on to you.
Drugs other than those listed here may also interact with daclizumab. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including vitamins, minerals, and herbal products.
See also: daclizumab side effects (in more detail)
Dépréotide may be available in the countries listed below.
Dépréotide (DCF) is also known as Depreotide (Rec.INN)
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Polyron may be available in the countries listed below.
Iron Polymaltose is reported as an ingredient of Polyron in the following countries:
International Drug Name Search
Rize may be available in the countries listed below.
Clotiazepam is reported as an ingredient of Rize in the following countries:
International Drug Name Search
